STOCK TITAN

Elanco Animal Health (NYSE: ELAN) director buys 10,000 shares at $23.69

(Moderate)
(Positive)
Form Type
4

Rhea-AI Filing Summary

Elanco Animal Health Inc director Paul Herendeen reported an open-market purchase of 10,000 shares of Common Stock on August 7, 2026 at $23.685 per share. Following this transaction, his reported direct ownership increased to 111,687 common shares of Elanco Animal Health Inc.

Positive

  • None.

Negative

  • None.
Insider Herendeen Paul
Role Director
Bought 10,000 shs ($237K)
Type Security Shares Price Value
Purchase Common Stock 10,000 $23.685 $237K
Holdings After Transaction: Common Stock — 111,687 shares (Direct)
Shares purchased 10,000 shares Common Stock acquired on August 7, 2026
Purchase price per share $23.685 per share Price paid for Common Stock on August 7, 2026
Shares owned after transaction 111,687 shares Direct holdings following the reported purchase
Common Stock financial
"security_title": "Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
open market or private transaction financial
"transaction_code_description": "Purchase in open market or private transaction"
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did ELAN director Paul Herendeen report?

Paul Herendeen reported purchasing 10,000 shares of Elanco Animal Health Inc common stock on August 7, 2026 at $23.685 per share in an open-market or private transaction.

How many ELAN shares does Paul Herendeen own after this Form 4 transaction?

After the reported purchase, Paul Herendeen’s direct holdings increased to 111,687 shares of Elanco Animal Health Inc common stock, as shown in the Form 4 filing’s post-transaction ownership figure.

Was the ELAN insider trade by Paul Herendeen a purchase or sale?

The Form 4 reports a purchase of Elanco Animal Health Inc common stock by Paul Herendeen, coded as transaction type P, which represents a purchase in an open market or private transaction.

What price did Paul Herendeen pay per ELAN share in this transaction?

The reported transaction price was $23.685 per share for the 10,000 Elanco Animal Health Inc common shares acquired on August 7, 2026, with the price identified as a per-share amount.

Was Paul Herendeen’s ELAN stock purchase under a Rule 10b5-1 trading plan?

The Form 4’s Rule 10b5-1 checkbox is not marked as affirmative, indicating the reported 10,000-share purchase was not identified in the form as being made pursuant to a Rule 10b5-1 trading plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Herendeen Paul

(Last)(First)(Middle)
C/O ELANCO ANIMAL HEALTH INCORPORATED
450 ELANCO CIRCLE

(Street)
INDIANAPOLIS INDIANA 46221

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/07/2026P10,000A$23.685111,687D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
/s/ Amy C. Seidel, as Attorney-in-Fact for Paul Herendeen08/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)